Crossmark Global Holdings Inc. Purchases 1,149 Shares of Danaher Co. (NYSE:DHR)

Crossmark Global Holdings Inc. grew its position in Danaher Co. (NYSE:DHR) by 2.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 40,990 shares of the conglomerate’s stock after acquiring an additional 1,149 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Danaher were worth $9,410,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC grew its holdings in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares in the last quarter. International Assets Investment Management LLC grew its stake in Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after buying an additional 428,897 shares during the last quarter. Montrusco Bolton Investments Inc. raised its stake in Danaher by 30.4% in the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after buying an additional 397,671 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec raised its stake in Danaher by 82.4% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 653,375 shares of the conglomerate’s stock valued at $181,651,000 after buying an additional 295,187 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 2.4 %

Shares of Danaher stock opened at $244.18 on Wednesday. The firm has a 50-day simple moving average of $234.75 and a two-hundred day simple moving average of $253.50. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher Co. has a fifty-two week low of $225.42 and a fifty-two week high of $281.70. The company has a market cap of $176.36 billion, a P/E ratio of 46.60, a price-to-earnings-growth ratio of 4.30 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.02 earnings per share. As a group, equities analysts predict that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DHR. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a report on Thursday, October 31st. TD Cowen raised their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Robert W. Baird dropped their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Citigroup lowered their price target on Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, Scotiabank began coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective on the stock. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.